Effectiveness of Acupuncture for Alzheimer’s Disease
Introduction to Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder marked by symptoms including memory loss, difficulties with language, disorientation, and alterations in personality and behavior. This chronic and progressive condition currently lacks a cure; although existing medications can slow its progression, they do not reverse its effects. Long-term care is essential for individuals with AD, as they often experience poor judgment and ultimately struggle with daily living activities. Improving the quality of life for both patients and caregivers is vital, particularly given the limitations and side effects associated with conventional treatments. This necessity has sparked interest in complementary therapies, such as acupuncture, which may present fewer side effects.
Need for Further Research on Acupuncture
Despite its potential, evidence supporting the use of acupuncture for Alzheimer’s disease is limited. More comprehensive studies are necessary to thoroughly assess its effectiveness.
Study Overview: Acupuncture versus Donepezil
Research Design and Methodology
A recent randomized, drug-controlled parallel group study conducted in China and published in BMC Complementary and Alternative Medicine explored the efficacy and safety of acupuncture compared to donepezil, a medication utilized to address cognitive and behavioral symptoms in Alzheimer’s patients. The study involved 87 patients with mild to moderate Alzheimer’s disease, who were randomly assigned to receive either acupuncture or donepezil. Researchers evaluated cognitive abilities, behavioral symptoms, and performance in daily activities at three intervals: upon enrollment, 16 weeks into the study, and 28 weeks after treatment completion.
Acupuncture Treatment Protocol
Participants in the acupuncture group underwent treatment three times a week over a 12-week period, administered by nine registered acupuncturists with at least six years of clinical experience. Treatment plans were customized based on the consensus of three experienced acupuncturists, with acupuncture points selected according to professional judgment. The donepezil group received 5 mg of the medication daily for the first four weeks, followed by an increase to 10 mg thereafter.
Results of the Study
Patient Outcomes
Out of the initial participants, 79 completed the study, with approximately 40 in each treatment group. No serious adverse events were reported, indicating that both treatments were well tolerated. Significant improvements in cognitive function were noted in the acupuncture group 28 weeks post-treatment compared to the donepezil group; however, no significant differences in cognitive function were observed at the 16-week mark.
Global Clinical Status and Additional Findings
The acupuncture group exhibited significant improvements in global clinical status at both the 16 and 28-week assessments compared to the donepezil group. Nevertheless, there were no significant differences in behavioral symptoms or daily living activities between the two groups. Notably, patients receiving acupuncture also reported enhancements in additional symptoms, including insomnia, constipation, and arthritis.
Conclusion and Future Directions
Implications of the Study
While the researchers could not definitively state that acupuncture is safer than donepezil, the findings suggest that acupuncture is a safe and well-tolerated treatment option that may enhance cognitive and overall clinical function in Alzheimer’s patients. However, the study’s limitations, such as a small sample size and recruitment from a single geographical area in China, raise questions regarding the generalizability of the results.
Need for Further Research
Additional research is necessary to further investigate the potential of acupuncture as a treatment for Alzheimer’s disease, including studies that explore the mechanisms behind its possible benefits, such as improved connectivity between brain regions.
Reference
Jia, Yujie, et al. “Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial.” BMC Complementary and Alternative Medicine 17.1 (2017): 556.
Written by Suzanne M. Robertson, Ph.D.